CL2017000040A1 - Inhibidores de aldosterona sintasa. - Google Patents

Inhibidores de aldosterona sintasa.

Info

Publication number
CL2017000040A1
CL2017000040A1 CL2017000040A CL2017000040A CL2017000040A1 CL 2017000040 A1 CL2017000040 A1 CL 2017000040A1 CL 2017000040 A CL2017000040 A CL 2017000040A CL 2017000040 A CL2017000040 A CL 2017000040A CL 2017000040 A1 CL2017000040 A1 CL 2017000040A1
Authority
CL
Chile
Prior art keywords
compounds
synthase inhibitors
aldosterone synthase
processes
refers
Prior art date
Application number
CL2017000040A
Other languages
English (en)
Inventor
Jennifer Burke
Derek Cogan
John Lord
Daniel Richard Marshall
Bryan P Mckibben
Maolin Yu
Yunlong Zhang
Matthew A Cerny
Lee Fader
Josea S Frederick
Simon Surprenant
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2017000040A1 publication Critical patent/CL2017000040A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A LOS COMPUESTOS DE LA FÓRMULA I:</p> <p>*INCLUIR FIGURA DE ESTRUCTURA DE HOJA RESUMEN DE FECHA 6-01-2017 (PAG 5)</p> <p>Y A LAS SALES DE ESTOS ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO, EN DONDE CY, R1 Y R2 SON COMO SE DEFINEN EN LA PRESENTE. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS, A MÉTODOS PARA USAR ESTOS COMPUESTOS EN EL TRATAMIENTO DE VARIAS ENFERMEDADES Y TRASTORNOS, A PROCESOS PARA PREPARAR ESTOS COMPUESTOS Y A INTERMEDIARIOS ÚTILES EN ESTOS PROCESOS.</p>
CL2017000040A 2014-07-24 2017-01-06 Inhibidores de aldosterona sintasa. CL2017000040A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462028556P 2014-07-24 2014-07-24

Publications (1)

Publication Number Publication Date
CL2017000040A1 true CL2017000040A1 (es) 2017-07-07

Family

ID=53761616

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000040A CL2017000040A1 (es) 2014-07-24 2017-01-06 Inhibidores de aldosterona sintasa.

Country Status (34)

Country Link
US (1) US9334285B2 (es)
EP (1) EP3172212B1 (es)
JP (1) JP6250862B2 (es)
KR (1) KR102378648B1 (es)
CN (1) CN106488921B (es)
AP (1) AP2016009616A0 (es)
AR (1) AR101290A1 (es)
AU (1) AU2015292632B2 (es)
BR (1) BR112017000584B1 (es)
CA (1) CA2956118C (es)
CL (1) CL2017000040A1 (es)
CO (1) CO2017000443A2 (es)
CY (1) CY1121063T1 (es)
DK (1) DK3172212T3 (es)
EA (1) EA031105B1 (es)
ES (1) ES2684050T3 (es)
HR (1) HRP20181441T1 (es)
HU (1) HUE039981T2 (es)
IL (1) IL249665B (es)
LT (1) LT3172212T (es)
MX (1) MX368093B (es)
MY (1) MY191352A (es)
NZ (1) NZ727188A (es)
PE (1) PE20170294A1 (es)
PH (1) PH12017500089A1 (es)
PL (1) PL3172212T3 (es)
PT (1) PT3172212T (es)
RS (1) RS57570B1 (es)
SG (1) SG11201700595RA (es)
SI (1) SI3172212T1 (es)
TW (1) TWI600658B (es)
UA (1) UA118801C2 (es)
UY (1) UY36228A (es)
WO (1) WO2016014736A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58651B1 (sr) * 2014-10-15 2019-05-31 Boehringer Ingelheim Int Inhibitori aldosteron sintaze
JP6707084B2 (ja) * 2014-12-02 2020-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルドステロンシンターゼ阻害薬
EP3475262B1 (en) * 2016-06-28 2021-03-24 Boehringer Ingelheim International GmbH Bicyclic imidazole derivatives useful for the treatment of renal disease, cardiovascular diseases and fibrotic disorders
SG10201610038SA (en) * 2016-07-29 2017-12-28 Apple Inc Systems and methods for management of asymmetrical multi-tapped battery packs
US11958818B2 (en) 2019-05-01 2024-04-16 Boehringer Ingelheim International Gmbh (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
WO2023114170A1 (en) 2021-12-14 2023-06-22 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors for treating chronic kidney disease
AU2024328580A1 (en) 2023-08-18 2026-02-05 Boehringer Ingelheim International Gmbh Inhibitors of trpc6 for treating focal segmental glomerulosclerosis
US20250255851A1 (en) 2024-02-14 2025-08-14 Boehringer Ingelheim International Gmbh Solid forms of an aldosterone synthase inhibitor
WO2025190858A1 (en) 2024-03-12 2025-09-18 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitor for treating heart failure

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100703068B1 (ko) * 2003-12-30 2007-04-05 에스케이케미칼주식회사 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
CN101410389A (zh) * 2006-03-29 2009-04-15 诺瓦提斯公司 有机化合物
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TWI577671B (zh) * 2011-11-14 2017-04-11 Sunshine Lake Pharma Co Ltd Aminoquinazoline derivatives and salts thereof and methods of use thereof
US8912341B2 (en) * 2013-01-16 2014-12-16 Northwestern University Enantioselective N-heterocyclic carbene-catalyzed annulation reactions with imidazolidinones

Also Published As

Publication number Publication date
UY36228A (es) 2016-01-29
TWI600658B (zh) 2017-10-01
BR112017000584B1 (pt) 2022-07-26
HRP20181441T1 (hr) 2018-11-02
PT3172212T (pt) 2018-10-08
EA201790253A1 (ru) 2017-07-31
CY1121063T1 (el) 2019-12-11
EA031105B1 (ru) 2018-11-30
KR102378648B1 (ko) 2022-03-28
SI3172212T1 (sl) 2018-10-30
EP3172212A1 (en) 2017-05-31
EP3172212B1 (en) 2018-06-13
US9334285B2 (en) 2016-05-10
PL3172212T3 (pl) 2018-11-30
PE20170294A1 (es) 2017-04-12
CO2017000443A2 (es) 2017-04-10
HUE039981T2 (hu) 2019-02-28
MX368093B (es) 2019-09-19
LT3172212T (lt) 2018-08-27
AR101290A1 (es) 2016-12-07
JP6250862B2 (ja) 2017-12-20
AU2015292632A1 (en) 2016-12-22
AP2016009616A0 (en) 2016-12-31
UA118801C2 (uk) 2019-03-11
PH12017500089B1 (en) 2017-05-22
BR112017000584A2 (pt) 2017-11-07
IL249665A0 (en) 2017-02-28
US20160024105A1 (en) 2016-01-28
SG11201700595RA (en) 2017-02-27
PH12017500089A1 (en) 2017-05-22
NZ727188A (en) 2020-01-31
DK3172212T3 (en) 2018-08-27
TW201619165A (zh) 2016-06-01
CN106488921A (zh) 2017-03-08
IL249665B (en) 2019-08-29
AU2015292632B2 (en) 2019-11-21
ES2684050T3 (es) 2018-10-01
KR20170032459A (ko) 2017-03-22
CN106488921B (zh) 2019-03-15
JP2017521466A (ja) 2017-08-03
CA2956118A1 (en) 2016-01-28
MX2017000929A (es) 2017-05-04
CA2956118C (en) 2022-11-15
MY191352A (en) 2022-06-18
RS57570B1 (sr) 2018-10-31
WO2016014736A1 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
ECSP24026455A (es) Compuestos de pirrolotriazina como inhibidores de tam
CL2017000040A1 (es) Inhibidores de aldosterona sintasa.
CL2017000071A1 (es) Acidos carboxílicos hterocíclicos como activadores de guanilato ciclasa soluble.
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
CL2017000089A1 (es) Espirocicloheptanos como inhibidores de rock
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
GT201600123A (es) Inhibidores de syk
MX2018005890A (es) Composiciones para tratar atrofia muscular espinal.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
CL2017000541A1 (es) Compuestos y composiciones como inhibidores de raf kinasa
UY37205A (es) Inhibidores de bromodominios
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
GT201600132A (es) Derivados de ácido heteroaril butanóico como inhibidores de lta4h
CL2017000827A1 (es) Inhibidores de aldosterona sintasa
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
CO2017000011A2 (es) Derivados de quinolizinona como inhibidores de pi3k
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
MX2017008373A (es) Compuestos, composiciones y metodos.
CL2016003230A1 (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
ECSP17003149A (es) Compuestos de dihidroisoquinolinona sustituida